OBJECTIVES: Factors other than efficacy and safety may influence choice of treatment for the patient. Barriers to intensification may lead to poor glycaemic control. This study aimed to assess patient barriers and behaviours relating to intensification of treatment in insulin-treated Type-2-diabetes (T2DM) in the Netherlands.  METHODS: Patients diagnosed >6 months ago and receiving insulin for ≥3 months were recruited through a representative online panel in the Netherlands. Data were collected using a web-based questionnaire. RESULTS: The 315 respondents had mean age of 59 years, BMI 31kg/m and 8-years insulin treatment. Of the 179 who knew their HbA, 45 (25.1%) were uncontrolled (>8%) with mean HbACONCLUSIONS: Patients on intensified regimens may require increase used of secondary care, whilst number/timing of injections, dose calculation, hypoglycaemia risk and weight gain are barriers to insulin intensification among T2DM patients on basal insulin. Therapies addressing these may help to achieve treatment goals.